Difference between revisions of "Epcoritamab (Epkinly)"
Jump to navigation
Jump to search
m |
|||
| Line 22: | Line 22: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category:BiTE antibodies]] | + | [[Category:Anti-CD20 BiTE antibodies]] |
[[Category:Anti-CD20 antibodies]] | [[Category:Anti-CD20 antibodies]] | ||
[[Category:Anti-CD3 antibodies]] | [[Category:Anti-CD3 antibodies]] | ||
Revision as of 15:09, 28 June 2023
General information
Class/mechanism from the NCI Drug Dictionary: A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells.
Route: IV
Extravasation: no information
Diseases for which it is used
History of changes in FDA indication
- 2023-05-19: Granted accelerated approval for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (Based on EPCORE NHL-1)
Also known as
- Code name: GEN-3013
- Generic name: epcoritamab-bysp
- Brand name: Epkinly